{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:47:04Z","timestamp":1776743224358,"version":"3.51.2"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2026.01.001","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:00:11Z","timestamp":1768838411000},"page":"226-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["FLAG-IDA LITE: A Reasonable Induction Regimen for Elderly AML Patients"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-5050","authenticated-orcid":false,"given":"Mercedes","family":"Colorado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa Aranzazu","family":"Berm\u00fadez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Dom\u00ednguez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7408-0926","authenticated-orcid":false,"given":"Guillermo","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-4469","authenticated-orcid":false,"given":"I\u00f1igo","family":"Romon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2026.01.001_bib0001","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2026.01.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.01.001_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.22192","article-title":"FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment","volume":"87","author":"Berm\u00fadez","year":"2012","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.clml.2026.01.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3945.3945","article-title":"Fludarabine and cytarabine based induction therapy is associated with high response rate and durable remission with low treatment related mortality in elderly patients with core-binding factor AML (CBF-AML)","volume":"122","author":"Takahashi","year":"2013","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.clml.2026.01.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.21.0674","article-title":"Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup","volume":"27","author":"Pr\u00e9bet","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.01.001_bib0006","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-11-4354","article-title":"Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from cancer and leukemia group B 8461","volume":"108","author":"Farag","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2026.01.001_bib14","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.01.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.12538","article-title":"Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older","volume":"95","author":"Vives","year":"2015","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2026.01.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.25.1496","article-title":"Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a cancer and leukemia group B study","volume":"28","author":"Becker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.01.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2009.07604.x","article-title":"The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial","volume":"145","author":"Burnett","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.01.001_bib0010","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020"},{"key":"10.1016\/j.clml.2026.01.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-134832","article-title":"Cytopenia management in patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study","volume":"136","author":"Pratz","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.01.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.01.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:18:40Z","timestamp":1776741520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265026000017"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FLAG-IDA LITE: A Reasonable Induction Regimen for Elderly AML Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}